Craft

Meridian Bioscience

Stock Price

$34

2023-01-30

Market Capitalization

$1.5 B

2023-01-30

Revenue

$333 M

FY, 2022

Meridian Bioscience Summary

Company Summary

Overview
Meridian Bioscience is a life science company which develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The Company offers testing platforms and technologies. These products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens.The Company also provides bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies.
Type
Public
Status
Active
Founded
1977
HQ
Cincinnati, OH, US | view all locations
Website
http://meridianbioscience.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Melissa McCarey

    Melissa McCarey, Vice President, Global Human Resources

    • Tony Serafini-Lamanna

      Tony Serafini-Lamanna, Executive Vice President, Diagnostics

      LocationsView all

      11 locations detected

      • Cincinnati, OH HQ

        United States

        3471 River Hills Dr

      • Eveleigh, New South Wales

        Australia

        Suite G16A, NIC Building Australian Technology Park

      • Braine-l'Alleud, Wallonie

        Belgium

        2 Avenue du Japon

      • Québec, QC

        Canada

        360 Rue Franquet #3

      • Paris, Île-de-France

        France

        34 Rue de Ponthieu

      • Luckenwalde, Brandenburg

        Germany

        3 Im Biotechnologiepark

      and 5 others

      Meridian Bioscience Financials

      Summary Financials

      Revenue (Q1, 2023)
      $56.9M
      Gross profit (Q1, 2023)
      $31.5M
      Net income (Q1, 2023)
      ($29.8M)
      Cash (Q1, 2023)
      $74.1M
      EBIT (Q1, 2023)
      ($28.1M)
      Enterprise value
      $1.4B

      Footer menu